| Literature DB >> 25475588 |
Diane T Smelser1, Gerard Tromp, James R Elmore, Helena Kuivaniemi, David P Franklin, H Lester Kirchner, David J Carey.
Abstract
BACKGROUND: Using abdominal aortic aneurysm (AAA) as a model, this case-control study used electronic medical record (EMR) data to assess known risk factors and identify new associations.Entities:
Mesh:
Year: 2014 PMID: 25475588 PMCID: PMC4269847 DOI: 10.1186/1471-2261-14-174
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
ICD-9 diagnostic codes and assigned categories used to identify comorbidities
| Diagnostic category | ICD-9 codes |
|---|---|
| Arterial dissection | 443.21–443.29 |
| Atherosclerosis | 440 |
| Benign neoplasm | 210.00–229.9, 238.8, 238.9 |
| Cerebral thrombosis | 434, 434.01, 434.1, 437.1 |
| Cerebrovascular disease | 434.11, 434.91, 435.8, 435.9, 436, 437, 437.0A, 437.4, 437.6–437.9 |
| Coronary stenosis | 411.81, 414.00–414.9 |
| Cranial artery stenosis | 433–433.9, 434.9, 435–435.3 |
| Hypertension | 401.0–405.99 |
| Intracranial aneurysm | 430, 437.3 |
| Intracranial hemorrhage | 431, 432.1, 432.9 |
| Kidney disease | 585.3–585.9, 586 |
| Malignant neoplasm | 140.00–209.6, 230.00–234.9, 235.1–238.3 |
| Myelogenous neoplasm | 200–208.9, 238.4–238.7, 238.71–238.73, 238.75, 238.76, 238.79, 272.2 |
| Peripheral artery disease | 440.21, 440.22, 440.3, 440.31, 440.32, 443.9 |
| Pulmonary disease | 491.00–492.8, 493.2, 496, 518.1 |
| Type 1 diabetes | 250.01, 250.03, 250.11, 250.13, 250.2, 250.23, 250.41, 250.43, 250.51, 250.53, 250.61, 250.63, 250.71, 250.73, 250.81, 250.83, 250.93 |
| Type 2 diabetes | 250.00, 250.02, 250.1, 250.12, 250.22, 250.4, 250.42, 250.5, 250.52, 250.6, 250.62, 250.7, 250.72, 250.8, 250.82, 250.9, 250.92 |
ICD-9, International Classification of Diseases (9th Revision).
Figure 1Study design. MyCode® is the biobank at GHS, Geisinger Health System. AAA, abdominal aortic aneurysm; EMR, electronic medical record.
Risk factor estimates for AAA
| Variable | Meta*estimate | Meta*SE |
| OR | 95% CI |
|---|---|---|---|---|---|
| Peripheral artery disease | 1.49 | 0.0040 | 3.71E-16 | 4.42 | 3.08–6.35 |
| Smoking, ever/never | 1.36 | 0.0036 | 3.92E-15 | 3.91 | 2.77–5.53 |
| Coronary stenosis | 1.07 | 0.0032 | 2.01E-12 | 2.91 | 2.15–3.93 |
| Type 2 diabetes | −0.84 | 0.0043 | 1.69E-05 | 0.43 | 0.29–0.64 |
| Systolic blood pressure | 0.03 | 0.0001 | 2.20E-07 | 1.03 | 1.02–1.05 |
| Diastolic blood pressure | −0.05 | 0.0003 | 1.84E-05 | 0.95 | 0.93–0.98 |
| Age | 0.05 | 0.0001 | 1.63E-15 | 1.05 | 1.04–1.06 |
| Weight | −0.01 | 3.94E-05 | 9.13E-07 | 0.99 | 0.98–0.99 |
| Height | 0.12 | 0.0001 | 2.78E-05 | 1.13 | 1.06–1.20 |
| Sex | 0.65 | 0.0044 | 0.00172 | 1.92 | 1.24–2.97 |
| Benign neoplasm | −0.39 | 0.0029 | 0.00263 | 0.67 | 0.51–0.89 |
| Pulmonary disease | 0.54 | 0.0035 | 0.00061 | 1.72 | 1.24–2.38 |
| Hypertension | 0.62 | 0.0038 | 0.00056 | 1.86 | 1.28–2.72 |
| Myelogenous neoplasm | −0.32 | 0.0032 | 0.02131 | 0.73 | 0.54–0.99 |
Controls chosen randomly from all non-AAA subjects (2,500 iterations, 500 cases, 2,000 controls), but weighted on sex and age (5 y classes) to match census population structure for the GHS catchment area. For outline of the study design, see Figure 1.
Age classes below 35 were consolidated into a single age class to avoid oversampling the sparse classes of [18, 20, 25] and [25, 30]. These classes are typically underrepresented in physician visits.
*Meta.Est is the meta-analysis estimate (random effects, variance weighted, aggregate) of the betas from bootstrap iterations, Meta SE is the standard error of this estimate.
†Two-sided P-value.
Comparison of subclasses of benign neoplasms between AAA cases and controls
| Type of neoplasm | Cases (n = 365) with neoplasm | Controls (n = 5419) with neoplasm |
| ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Skin | 216 | 59.18 | 3962 | 73.11 | <0.001 |
| Digestive | 226 | 61.92 | 2317 | 42.76 | <0.001 |
| Benign Neoplasm NOS* | 61 | 16.71 | 764 | 14.1 | 0.164 |
| Lipoma | 31 | 8.49 | 632 | 11.66 | 0.074 |
| Hemangioma | 12 | 3.29 | 248 | 4.58 | 0.296 |
| Endocrine gland | 22 | 6.03 | 211 | 3.89 | 0.053 |
| Eye | 10 | 2.74 | 106 | 1.96 | 0.33 |
| Brain/nervous | 7 | 1.92 | 104 | 1.92 | 0.98 |
| Soft tissue | 2 | 0.55 | 88 | 1.62 | 0.126 |
| Mouth/throat | 11 | 3.01 | 82 | 1.51 | 0.048 |
| Respiratory | 6 | 1.64 | 37 | 0.68 | 0.051 |
| Urinary | 2 | 0.55 | 21 | 0.39 | 0.654 |
| Bone | 0 | 0 | 10 | 0.18 | 0.969 |
*NOS = Not otherwise specified.
Cases and controls used for this analysis include those with at least one diagnosis of benign neoplasm. Controls which were selected at least 100 times in the bootstrap replication sets to provide a more closely matched comparison group.
†χ2or Fisher’s exact test where appropriate, P- values are 2-tailed.
Figure 2Forest plot of risk factors for AAA identified using EMR data. For scaling purposes, the data are separated into. A, discrete variables; and B, continuous variables. Odds ratios and 95% confidence intervals for the variables associated with AAA are shown. PAD, peripheral artery disease; T2DM, type 2 diabetes mellitus; BP, blood pressure.